Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
1. Baxdrostat [inn]
2. Nf3p9z8j5y
3. (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide
4. 1428652-17-8
5. N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamide
6. Propanamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)-
7. Unii-nf3p9z8j5y
8. Chembl4113975
9. Schembl14799753
10. Bdbm233806
11. Hy-132809
12. Cs-0204056
13. Us9353081, 3-1
| Molecular Weight | 363.5 g/mol |
|---|---|
| Molecular Formula | C22H25N3O2 |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 363.19467705 g/mol |
| Monoisotopic Mass | 363.19467705 g/mol |
| Topological Polar Surface Area | 62.3 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 566 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Baxdrostat, a miscellaneous product targeting aldosterone synthase, shows promise in treating hypertension.
Lead Product(s): Baxdrostat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Baxfendy
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 18, 2026
Lead Product(s) : Baxdrostat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fda Approves AstraZeneca Hypertension Treatment Baxfendy
Details : Baxdrostat, a miscellaneous product targeting aldosterone synthase, shows promise in treating hypertension.
Product Name : Baxfendy
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2026
Details:
Baxdrostat is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Baxdrostat,Dapagliflozin
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 30, 2025
Lead Product(s) : Baxdrostat,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dapagliflozin Plus Baxdrostat vs Baxdrostat on Kidney Disease Albumin
Details : Baxdrostat is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2025
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperaldosteronism.
Lead Product(s): Baxdrostat,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2025
Lead Product(s) : Baxdrostat,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy & Safety of Baxdrostat in Patients with Primary Aldosteronism
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hyperaldosteronism.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2025
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Baxdrostat,Dapagliflozin
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Baxdrostat,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.
Lead Product(s): Baxdrostat,Dapagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2024
Lead Product(s) : Baxdrostat,Dapagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2024
Details:
Ethinyl estradiol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Ethinyl Estradiol,Levonorgestrel,Baxdrostat
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 24, 2024
Lead Product(s) : Ethinyl Estradiol,Levonorgestrel,Baxdrostat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ethinyl estradiol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2024
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Baxdrostat,Itraconazole
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2024
Lead Product(s) : Baxdrostat,Itraconazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2024
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Lead Product(s): Baxdrostat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2024
Lead Product(s) : Baxdrostat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension.
Lead Product(s): Baxdrostat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : Baxdrostat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2024
Details:
Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): Baxdrostat,Dapagliflozin
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 20, 2024
Lead Product(s) : Baxdrostat,Dapagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Baxdrostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : USA
Brand Name : BAXFENDY
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number : 219878
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : USA
Brand Name : BAXFENDY
Dosage Form : TABLET;ORAL
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number : 219878
Regulatory Info :
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD :
TE Code :
Brand Name : BAXFENDY
Dosage Form : TABLET;ORAL
Dosage Strength : 1MG
Approval Date :
Application Number : 219878
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : BAXFENDY
Dosage Form : TABLET;ORAL
Dosage Strength : 2MG
Approval Date :
Application Number : 219878
RX/OTC/DISCN :
RLD :
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
WEEKLY NEWS RECAP #Phispers
NEWS #PharmaBuzz
ABOUT THIS PAGE
38
PharmaCompass offers a list of Baxdrostat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Baxdrostat manufacturer or Baxdrostat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Baxdrostat manufacturer or Baxdrostat supplier.
A Baxdrostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Baxdrostat, including repackagers and relabelers. The FDA regulates Baxdrostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Baxdrostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Baxdrostat supplier is an individual or a company that provides Baxdrostat active pharmaceutical ingredient (API) or Baxdrostat finished formulations upon request. The Baxdrostat suppliers may include Baxdrostat API manufacturers, exporters, distributors and traders.
Baxdrostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Baxdrostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Baxdrostat GMP manufacturer or Baxdrostat GMP API supplier for your needs.
A Baxdrostat CoA (Certificate of Analysis) is a formal document that attests to Baxdrostat's compliance with Baxdrostat specifications and serves as a tool for batch-level quality control.
Baxdrostat CoA mostly includes findings from lab analyses of a specific batch. For each Baxdrostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Baxdrostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Baxdrostat EP), Baxdrostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Baxdrostat USP).
